A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: ZEN003694|DRUG: Talazoparib
Sponsor: Zenith Epigenetics
Collaborators: Pfizer|Newsoara Biopharma Co., Ltd.